INTRODUCTION
============

Chagas disease is classified as a neglected tropical disease caused by the protozoan *Trypanosoma cruzi*. It occurs in several countries, especially in Latin America, where it is estimated that about 6 to 8 million people are infected^[@B1]^. The disease is divided into two distinct phases: an initial acute phase and a chronic phase; the manifestations of the latter can take decades to occur^[@B2]^. The drugs available for its treatment are benznidazole and nifurtimox, which have limited efficacy and serious adverse effects, especially in the chronic phase^[@B1],[@B3]^. Currently, benznidazole is considered the drug of choice for the treatment of the disease in Brazil^[@B2],[@B3]^.

The recommended dose of benznidazole for adult patients with Chagas disease in the chronic phase is 5 mg/kg/day, divided into two daily doses for a period of 60 days^[@B4]-[@B6]^. However, adverse effects have been observed since the beginning of its use so that in 12 to 18% of adult patients at this stage of the disease, treatment has to be discontinued due to such effects. Thus, both, dose and duration of treatment are still being discussed in order to ensure greater patient safety^[@B6]^.

Diverging results in studies with the recommended dose have been found, especially regarding the duration of treatment. In the study conducted by Álvarez *et al*.^[@B6]^ no differences in the effectiveness of standard doses of benznidazole were observed between 30 and 60 consecutive days of administration, monitored by serial xenodiagnostics. In the study by Soy *et al.* ^[@B4]^, it was shown that the standard dose may be a significant overdose for some patients. According to Álvarez *et al*.^[@B6]^, the effective dose may be lower than the standard one proposed, and the best administration regimen to prevent or reduce adverse effects may not yet be known.

In addition, differences in the outcomes found in the studies could create barriers to treatment and even lead patients to experience worse health outcomes^[@B7]^. Thus, investigations are underway, and aiming at improving the therapy with benznidazole, its efficacy and safety, lower drug levels and shorter and/or intermittent regimens of the drug are being evaluated, either alone or in combination with other compounds^[@B8]^.

Given the above, the present study aimed to review the literature and evaluate the best dose regimen for benznidazole treatment in adult patients with Chagas disease in the chronic phase.

MATERIALS AND METHODS
=====================

Study design
------------

This is a review followed by meta-analysis, performed according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses)^[@B9]^ guidelines.

Elegibility criteria
--------------------

The "PICOS" process was established as: P (problem): adult patients with Chagas disease in the chronic phase; I (intervention): use of benznidazole; C (control): dose recommended by the literature; O (outcome): polymerase chain reaction (PCR) values, maintenance of cardiac conditions, negative seroconversion, reduction of clinical adverse events; S (study design): clinical trials and observational studies. According to "PICOS" the guiding question was defined: "What is the optimal dose regimen for benznidazole in adult patients with chronic Chagas disease?"

According to our inclusion criteria all the clinical trials or observational studies that evaluated adults patients with Chagas disease in the chronic phase and using benznidazole were considered eligible. Review articles, letters to the editor, opinion articles, studies on patients with Chagas disease using benznidazole only in the acute phase, preclinical studies, studies on pregnant women, children, and immunosuppressed patients were excluded.

Information source
------------------

The systematic review was performed in the PubMed, Science Direct, Virtual Health Library, and Scopus databases, including studies published until May 2019, with no restrictions on collection start date and language.

Search strategy
---------------

The descriptors were selected in consultation with the Medical Subject Heading (MeSH) and the following fixed descriptors were considered: "Chagas disease" and "benznidazole", which were cross referenced using the AND connector with: "Drug Therapy", "Pharmacokinetics", "Dose-response relationship, drug" and finally, with "Chronic disease". The selection, inclusion, and exclusion processes were performed by independent evaluators (VPF and NSS) and a third reviewer (CS), in case of disagreements.

Methodological quality assessment
---------------------------------

Methodological quality was assessed by two reviewers (VPF and NSS), using the Downs and Black^[@B10]^ scores. This tool has 27 items that can be evaluated in five subclasses: communication, external validity, internal validity, selection bias and study power, with scores higher than 15 being considered as quality studies^[@B10]^.

Data extraction
---------------

After reading in full, the following variables from the articles that met the inclusion criteria were collected: year of publication, country, sample size, dose regimen used, follow-up period after treatment, observed outcomes, and limitations presented by the authors.

Data analysis
-------------

A large number of articles in which benznidazole was administered at 5mg/kg/day during 30 or 60 days of treatment were found and they were all selected for analysis. The meta-analysis was calculated using a randomized 95% confidence interval model. The RStudio^®^ software was used for this analysis. The meta and metafor packages were used, along with the metaprop and metabin commands. Statistical heterogeneity between studies was analyzed and inconsistency was estimated by Square (I^2^) statistics, and considered up to 50%. To explore this heterogeneity, time-separated subgroup analyzes of benznidazole treatment were performed. The comparison between 30 and 60 days of treatment was made in order to evaluate the optimal treatment time of benznidazole at a dose of 5 mg/kg/day, observed through the outcomes: PCR, cardiac alterations and serology. In the articles that evaluated more than one outcome, the results were considered in the order in which they are cited above. We have also compared studies that used the PCR assay and/or negative seroconversion as an outcome.

RESULTS
=======

A total of 608 articles were found and among them, 580 were selected for analysis as 28 were duplicates. After reading titles and abstracts, 543 studies were excluded because they were review articles, opinions and/or editorial letters, or articles with patients in the acute phase of Chagas disease, according to the exclusion criteria. A total of 37 studies were then selected for full reading. Of these, two did not meet our inclusion criteria because they included children, adolescents and/or immunosuppressed patients, and other twelve did not fit the inclusion criteria and were excluded. Therefore, 23 articles were included in the final analysis ([Figure 1](#f01){ref-type="fig"}).

Figure 1Selection of items for the systematic review adapted from the PRISMA flowchart11

Of the included studies, 43.5% (n = 10) had a sample size smaller than or equal to 50 individuals^[@B6],[@B11]-[@B19]^ and 56.5% (n = 13) greater than 50 individuals^[@B20]-[@B32]^. Five articles (21.7%)^[@B11]-[@B13],[@B19],[@B21]^ had a higher risk of methodological bias, with scores lower than 15 in the quality assessment according to Downs and Black^[@B10]^, who claimed that the factors related to the potential confounders are the most affected.

The dose schedules of benznidazole used in the studies were diverse, ranging from 2.5mg/kg/day to 10mg/kg/day, lasting 30 to 80 days of treatment. The predominant regimen was 5mg/kg/day for 60 days, 39.1% (n = 9)^[@B6],[@B12],[@B13],[@B16]-[@B19],[@B28]-[@B30]^, followed by 5mg/kg/day for 30 days, 17.4 % (n = 4)^[@B22],[@B24],[@B31],[@B32]^. Follow-up after benznidazole treatment ranged from 45 days to 21 years ([Table 1](#t1){ref-type="table"}).

Table 1Studies evaluating benznidazole dosing regimens in adult patients with chronic Chagas disease (n=23)Author/CountrySample sizeTreatment regimen of benznidazoleFollow-up period post treatmentAnalyzed outcomeLimitationsAlvarez *et al*.^6^ ArgentinaTotal sample size n=20 qPCR n= 175 mg/kg/day, divided into two daily doses every 5 days, for a total of 60 days (12 days of intermittent treatment).67 daysPCR Adverse effects: severity and suspension rateThe efficacy of treatment as measured by qPCR was limited to a short-term follow-up period. Thecomparison of quantitative PCR (qPCR) occurred before and one week after the end of treatment. .Andrade *et al*.^12^ BrazilTotal sample size n=13 BNZ n=135 mg/kg/day/60 days4 yearsSerological parameters Cardiac conditions-Andrade *et al*.^13^ BrazilTotal sample size n=30 BNZ n=305 mg/kg every 8 hours/ 60 days6 yearsSerological parameters Cardiac conditionsDifficulty to perform the follow-up for a long period of time as the patient\'s lived in rural areas.Antunes *et al.* ^20^ BrazilTotal sample size n=241 BNZ n=43 BNZ ≤ 60 days, n=28 (50 days n = 5; 60 days n = 23) BNZ \> 60 days; n=15 (90 days n=4, 100 days n=4, 120 days n=3, 180 days n=1, 200 days n=1,250 days n=1, 700 days n=1) Control group (untreated) n=198No dose information BNZ for 50-60 daysUntil 700 daysPCR Cardiac conditionsBias and the absence of information in the study population relating to dosage and the length of time after treatment completion; The adoption of positive ELISA results in the inclusion criteria may have led to the exclusion of serologically cured patients, thereby reducing the ability to detect differences favoring the treatment; The small sample population probably reduced the statistical power to detect differences.Braga *et al*.^21^ BrazilTotal sample size n=51 BNZ n=17 BNZ/30 days: n=7 BNZ/60 days: n=10 Untreated group n=17 Control group (non-Chagas individuals) n=1710 mg/Kg/day/30 or 60 days10 yearsPCR Molecular method-Coura *et al*.^22^ BrazilTotal sample size n=77 Nifurtimox n=27 BNZ n=26 Control group (placebo) n=245 mg/kg/twice daily/ 30 days1 yearParasitological, serological and clinical parameters (cardiac conditions)-Fabbro *et al*.^23^ ArgentinaTotal sample size n=111 Nirfutimox n=27 BNZ n=27 Control group (untreated) n=575 mg/kg/day/30 days with half of the dose in the first week.21 yearsParasitological, serological and clinical parameters (cardiac conditions)There was lack of randomization of the groups, as most infected patients whose xenodiagnosis were positive, received treatment.Fernández *et al.* ^11^ ArgentinaTotal sample size n=6 BNZ n=62.5-5.5 mg/Kg/60 days (2.50, 2.60, 4.12, 4.55, 4.55, 5.48)06 monthsPCR-Lana *et al*.^14^ BrazilTotal sample size n=28 BNZ n=285-10 mg/kg/day for 40-60 consecutive days9 yearsPCR Parasitological, serological and clinical parameters (cardiac conditions)There was a low number of available samples. There was no intrinsic control group.Laucella *et al.* ^24^ ArgentinaTotal sample size n=75 BNZ n=43 Control group (untreated) n=325 mg/kg/day/ 30 days3-5 yearsImmunological, serological and clinical parameters-Levi *et al*.^15^ BrazilTotal sample size n=49 BNZ n=41 NirfutImox n=85 mg/kg/day to 8 mg/kg/day/60 daysRanged from 1 to 20 years (mean: 6 years. 7 months).Parasitological parameters-Molina *et al*.^25^ Bolivia, Brazil and ParaguayTotal sample size n=78 BNZ n=26 High-dose POS n=26 Low-dose POS n=26150 mg twice daily/ 60 days10 monthsPCR Adverse effects: suspension ratePCR results were not used as a measure of efficacy or cure, only as a marker of treatment failure.Morillo *et al*.^26^ Argentina, Bolivia, Brazil, Colombia and El SalvadorTotal sample size n=2854 BNZ n=1431 Control group (placebo) n=1423300 mg per day with a variable duration of therapy (40 to 80 days)5.4 yearsPCR Cardiac conditionsThe 95% confidence intervals rule out a relative risk reduction of 20%, which is smaller than the difference that the study was designed to detect.Morillo *et al*.^27^ Argentina, Chile, Colombia, Guatemala, Mexico and SpainTotal sample size n=120 POS n=30 BNZ+placebo n=30 POS + BNZ n=30 Control group (placebo) n=30POS:400 mg twice daily/60 days BNZ+placebo:200 mg daily/60 days POS+BNZ: 400+200 mg twice daily/60 days Placebo:10 mg twice daily/ 60 days1 yearPCRFollow-up was limited to only one year and the effect of trypanocidal treatment on progression to cardiomyopathy is unknown.Oliveira *et al*.^16^ BrazilTotal sample size n=45 BNZ n=21 Control group (untreated) n=245 mg/kg twice daily/60 days6 monthsBlood culture PCR Cardiac conditionsThe small number of treated patients. Most subjects in the chronic phase of the disease did not fulfill the inclusion criteria, limiting the number of patients The effects of BNZ during treatment or for a long time after treatment were not investigated.Pérez-Antón *et al.* ^19^ SpainTotal sample size n=50 BNZ n=38 Control group (non-Chagas individuals) n=125 mg/kg/day/60 days4 yearsPCR Immunological parameters-Perez-Mazliah *et al*.^17^ ArgentinaTotal sample size n=50 Allopurinol and BNZ n=15 Untreated subjects n=17 BNZ alone n=9 Control group (non-Chagas individuals) n=9Allopurinol: 600 mg/day/90days followed by 30 days of BNZ (5 mg/kg/day)3 yearsImmunological, Serological and clinical parameters-Pinazo *et al*.^28^ SpainTotal sample size n=54 BNZ n=545 mg/kg/day/ 60 days1 yearAdverse effects Biochemical and hematology testingThe serum concentrations of benznidazole metabolites were not measured and they might play an important role in toxicity.Pinazo *et al*.^29^ SpainTotal sample size n=99 BNZ n=56 Control group (non-Chagas individuals) n=435 mg/kg/day/ 60 days3 yearsHemostasis tests PCR Biochemical testing Basic blood testingA larger sample could have detected differences that would be expected to appear earlier (e.g., before 12 months). The lost to follow-up samples affected the estimates. It is difficult to follow-up individuals with high migratory mobility for long periods. The fact that only 30% of patients had a positive baseline qRT-PCR result was a constraint for assessing the effect of treatment.Torrico *et al*.^30^ BoliviaTotal sample size n=560 BNZ n=45 Control group (untreated) n=895 mg/kg/day/ 60 days1 yearPCR Serological parameters-Vallejo *et al*.^33^ SpainTotal sample size n=14 BNZ n=7 Control group (untreated) n=75 mg/kg twice daily/ 60 days18 monthsPCR Immune parametersSmall sample size. Problems with the follow-up of some patients that have impaired the analysis of parameters at specific time points.Viotti *et al*.^31^ ArgentinaTotal sample size n=566 BNZ n=283 Control group (untreated) n=2835 mg/kg/day/ 30 daysMedian time 9.8 yearsSerological parameters Cardiac conditions Disease progression (defined as a change to a more advanced Kuschnir group or death).Non-random, unblinded treatment assignment was used, and follow-up data were missing for 20% of the patients. Loss to follow-up was more common among patients who were less sick.Viotti *et al*.^32^ ArgentinaTotal sample size n=142 BNZ n=53 Control group (untreated) n=895 mg/kg/day/ 30 days3 yearsSerological parameters Cardiac conditionsThe non-randomized design. Results should be also extrapolated with caution due to the possibility that diverse *T. cruzi* lineages may have different susceptibilities to BNZ.[^2]

Regarding the outcomes observed by the authors, 56.5% (n = 13) of the studies used the PCR assay^[@B6],[@B11],[@B14],[@B16],[@B19]-[@B21],[@B25]-[@B27],[@B29],[@B30],[@B33]^, and 43.5% (n = 10) evaluated the cardiac conditions of the participants^[@B12]-[@B14],[@B16],[@B20],[@B22],[@B23],[@B26],[@B31],[@B32]^. A total of 43.5% (n = 10) used serological parameters^[@B12]-[@B14],[@B17],[@B22]-[@B24],[@B30]-[@B32]^ and 17.4% (n = 4) used parasitological parameters to evaluate the benznidazole treatment^[@B14],[@B15],[@B22],[@B23]^ ([Table 1](#t1){ref-type="table"}).

The main limitations observed in the studies were difficulties during the follow-up period, such as loss or short follow-up time, 30.4% (n = 7)^[@B6],[@B13],[@B16],[@B18],[@B27],[@B29],[@B31]^, in addition to the small sample size, 21.7% (n = 5)^[@B14],[@B16],[@B18],[@B20],[@B29]^ ([Table 1](#t1){ref-type="table"}).

Negative qualitative PCR results were found in all the studies that used PCR as an outcome, and 14.8 to 100.0% of negative patients after treatment were observed^[@B6],[@B11],[@B14],[@B16],[@B18]-[@B20],[@B25]-[@B27],[@B29],[@B30]^. Cases of cardiac conditions worsening were found in 60.0% (n = 8) of the studies that evaluated these conditions, with 3.7 to 38.2% of participants with such worsening conditions^[@B12],[@B13],[@B17],[@B23],[@B24],[@B30]-[@B32]^. Finally, cases of seronegativation were observed in 80% (n = 8) of the studies evaluating this parameter, being observed from 4.6 to 73.0% of participants with negative serology after benznidazole use^[@B12],[@B13],[@B17],[@B23],[@B24],[@B30]-[@B32]^. In 60.9% (n = 14) of the studies, adverse effects were reported, such as: gastrointestinal symptoms, dermatitis, cutaneous reactions, among others^[@B6],[@B11],[@B14],[@B15],[@B17],[@B18],[@B20],[@B22],[@B23],[@B25]-[@B28],[@B30]^ ([Table 2](#t2){ref-type="table"}).

Table 2Negative PCR results, cardiac conditions, seronegativation; negative parasitological tests after treatment with benznidazole and adverse events observed during the treatment.AuthorTreatment scheme of benznidazolePCR results (%)Cardiac conditions (%)Serological parameters (%)Parasitological parameters negative results (%)Adverse effectsAlvarez *et al*.^6^5 mg/kg/day, divided into two daily doses every 5 days, for a total of 60 days94.0\-\--Dermatitis (35.0%); gastrointestinal intolerance (25.0%); increased liver enzymes (20.0%); loss of appetite (5.0%); insomnia (5.0%). No serious adverse effects.Andrade *et al.* ^12^5 mg/kg/day/60 days-Maintained: 62.9Unchanged: 69.2 Regressive: 23.1 Progressive: 7.7\--Andrade *et al.* ^13^5 mg/kg every 8 hours/60 days-Maintained: 76.2 Worsening: 19.0Unchanged: 80.0 Regressive: 10.0 Progressive: 10.0 -Antunes *et al.* ^20^No dose information. BNZ for 50-60 days; BNZ \> 60 days.BNZ ≤60 days: 77.8 BNZ \>60: 66.7Maintained: 100.0\--Allergic reactions (19.5%)Braga *et al*.^21^10 mg/Kg/day/ 30 or 60 days\< 1 to 36 *T. cruzi*/ml (means 6.45 ± 9.28)\-\-\--Coura *et al*.^22^5 mg/kg/twice daily/ 30 days-Maintained: 100.0Unchanged: 100.098.2Rash, peripheral neuropathy gastrointestinal disorders. The adverse effects were discrete or moderate.Fabbro *et al.* ^23^5 mg/kg/day/ 30 days with half of the dose in the first week.-Worsening: 3.7Unchanged: 44,4 Regressive: 33,3 Progressive: 22,2100.0Maculopapular erythema (12.5%); pruritus and edema (3.7%). These patients had to stop the medication because of intolerance.Fernández *et al.* ^11^2.5-5.5 mg/Kg/ 60 days100.0\-\--Dermatitis, pruritus, oral mucositis, dysgeusia, paresthesia in lower limb, hypereosinophilia.Lana *et al*.^14^5-10 mg/kg/day for 40-60 consecutive days14.8Worsening: 4.6Unchanged: 100.092.9Anorexia, muscle pain, exanthema. One case of severe adverse effects was documented.Laucella *et al.* ^24^5 mg/kg/day/30 days\--Unchanged: 81.5 Regressive: 13.9 Progressive: 4.6\--Levi *et al*.^15^5 mg/kg/day to 8 mg/kg/day/60 days\-\--63.4Vesicular rash, peripheral neuropathy and psychiatric manifestations, leading to discontinuation of treatment in 41.5% of the patients.Molina *et al*.^25^150 mg twice daily/ 60 days61.5\-\--Severe cutaneous reactions (6.4%) leading to discontinuation of treatment.Morillo *et al*.^26^300 mg per day with a variable duration of therapy (between 40 to 80 days)At the end of the treatment: 66.2; 2 years: 55.4; 5 years or more: 46.7Worsening at 2 years: 36.7; Worsening at 5 years or more: 38.2\--Cutaneous rash, gastrointestinal symptoms, and nervous system disorders leading to discontinuation of treatment in 23.9% of the patients.Morillo *et al*.^27^20 0mg daily/ 60 daysBNZ+POS: 30 days: 88.9 60; days: 92.3; 360 days: 96.0 BNZ: 30 days: 89.7; 60 days: 89.3; 360 days: 96.0\-\--Severe adverse events (7.0%): cutaneous rash, nervous system disorders and gastrointestinal signs and symptoms.Oliveira *et al*.^16^5 mg/kg twice daily/ 60 days76.2There was worsening of the heart rate.\-\--Pérez-Antón *et al*.^19^5 mg/kg/day/ 60 days52.6\-\-\--Perez- Mazliah *et al.* ^17^Allopurinol: 600 mg/day/ 90 days followed by 30 days of BNZ (5 mg/kg/day)\--Regressive: 73.0-Mild dermatitis (26.7%), moderate dermatitis (26.7%). Treatment discontinuation was required in two cases (13%): one during treatment with allopurinol and one during treatment with BNZ.Pinazo *et al*.^28^5 mg/kg/day/ 60 days\-\-\--Gastrointestinal symptoms (76.0%); skin symptoms (74.0%), neurological/ musculoskeletal symptoms (74.0%), pruritus (70.0), fever (15.0%). Treatment was discontinued in 11 patients, 7 among them due to severe adverse effects.Pinazo *et al*.^29^5 mg/kg/day/ 60 days75.0\-\-\--Torrico *et al.* ^30^5 mg/kg twice daily/ 60 days97.0-Unchanged: 87.0 Regressive: 9.0 Inconclusive: 4.0-Severe adverse events: 4.0%Vallejo *et al.* ^33^5 mg/kg twice daily/ 60 days100.0\-\--Maculopapular rash, facial rash, fever, rash. Three discontinued therapy owing to adverse reactions.Viotti *et al*.^31^5 mg/kg/day/30 days-Worsening: 5.0Regressive: 15.0\--Viotti *et a*l.^32^5 mg/kg/day/30 days-Maintained: 100.0Regressive: 40.0\--

The clinical heterogeneity of the studies included in the meta-analysis was statistically significant, with an I^2^ of 90.0% for the nine articles (p \<0.01) ([Table 3](#t3){ref-type="table"}). For the group that used benznidazole for 60 days, I^2^ was 84% and for the group that used for 30 days, I^2^ was 60%. Pooled data from studies that used benznidazole for 30 days tended to have better results of the observed parameters (PCR, cardiac alterations and seroconversion) after treatment than those that used benznidazole for 60 days. For those who used PCR as the outcome, the risk of a negative result was 0.41 times higher after the end of treatment ([Table 4](#t4){ref-type="table"}) and for those who were analyzed by serology, the risk of negative serology was 3.65 times higher after treatment ([Table 5](#t5){ref-type="table"}).

Table 3Evolution of PCR parameters, cardiac conditions and serology among studies on benznidazole treatment for 30 and 60 days.StudyEventsTotalProportion 95% CI **Time of treatment: 60 days**    Andrade et al.^12^8130.62 \[0.32; 0.86\]![](1678-9946-rimtsp-62-S1678-9946202062052-e01.jpg)Andrade et al.^13^16210.76 \[0.53; 0.92\]Oliveira et al.^16^16210.76 \[0.53; 0.92\]Pérez-Antón et al.^19^38381.0 \[0.91; 1.00\]Pinazo et al.^29^55560.98 \[0.90; 1.00\]Vallejo et al.^33^771.0 \[0.50; 1.00\]**Subtotal (95% CI)** **1560.93 \[0.71; 0.99\]**Total Events140  Heterogeneity: I^2^ = 84%, π^2^ = 2.8331, p = 0.09**Time of treatment: 30 days**   Coura et al.^22^26261.00 \[0.87; 1.00\]Viotti et al.^31^2682830.95 \[0.91; 0.97\]Viotti et al.^32^53531.00 \[0.93; 1.00\]**Subtotal (95% CI)** **3620.99 \[0.69; 1.00\]**Total Events347  Heterogeneity: I^2^ = 60%, π^2^ = 1.6063, p = 1.00**Total (95% CI)** **5180.97 \[0.84; 0.99\]**Total Events487  Heterogeneity: I^2^ = 90%, π^2^ = 3.8301, p \< 0.01Residual heterogeneity: I^2^ = 25%, p = 0.23

Table 4Risk of negative PCR results before and after benznidazole treatment.**StudyBeforeAfterWeightRR95% CI** **EventsTotalEventsTotal**Alvarez *et al*.^6^Oliveira *et al*.^16^Pérez Antón *et al*.^19^Pinazo *et al*.^29^Vallejo *et al*.^33^**Total (95% CI)Total events**6018400**64**172138567139161638557**132**17213856713925.4%4.8%31.4%41.2%5.6%0.38 \[0.19; 0.72\]0.03 \[0.00; 0.47\]0.48 \[0.35; 0.67\]0.73 \[0.61; 0.86\]0.07 \[0.00; 0.97\]**0.41 \[0.21; 0.79\]**![](1678-9946-rimtsp-62-S1678-9946202062052-e02.jpg)Heterogeneity: I^2^ =85%, t^2^ = 0.3255, *p* = \<0.01  

Table 5Relative risk of negative serology after benznidazole treatment.**StudyExperimentalControlWeightRR95%CI** **EventsTotalEventsTotal**Laucella *et al*.^24^Viotti *et al*.^31^Viotti *et al*.^32^Torrico *et al*.^30^**Total (95% CI)Total events**632215**64**43218534535911262**21**3221289894225.2%54.8%31.3%8.7%4.47 \[0.57; 35.28\]2.59 \[1.37; 4.90\]5.88 \[2.53; 13.63\]4.94 \[1.00; 24.49\]**3.65 \[2.28; 5.84\]**![](1678-9946-rimtsp-62-S1678-9946202062052-e03.jpg)Heterogeneity: I^2^ = 0%, t^2^ = 0, *p* = 0.47

DISCUSSION
==========

The present review evaluated 23 studies that tested different benznidazole dose regimens in the chronic phase of Chagas disease. Our results pointed out that there was no consensus in the literature regarding dose, treatment time and cure criteria.

In most studies, the standard dose of 5 mg/kg/day was used, only varying the treatment time. Comparing the studies that used this dose for 30 and 60 days, it was observed that long-term treatment does not bring great benefits to the user. Through the meta-analysis, it was noticed that those who used benznidazole for a shorter time showed a tendency of better results of the observed parameters.

One great difficulty in the follow up of patients with Chagas disease is criteria to define cure, because there is not a consensual biomarker. The confirmation of cure varies according to the duration of disease, age, comorbidities, tests used, and time of follow-up after treatment^[@B34],[@B35]^.

Thus, it must be taken into account that the outcomes evaluated in the studies included in the meta-analysis are complex and have a heterogeneous distribution. In addition, we analyzed cardiac conditions without observing the clinical form of the chronic disease at baseline, considering only the improvement or maintenance of initial conditions. In the groups of the included studies, the participants' follow-up periods varied widely, from six months to 9.8 years. It is worth mentioning that the follow-up time is an important variable since, as previously mentioned, there is no consensual marker for the cure of the disease. Its evolution takes time, and the specific antibody titers for *T.cruzi* take a long time to decrease. Therefore, long-term investigations are needed to detect reliable negative results^[@B8],[@B36]^.

Besides the factors associated with cure, the studies that adopted 60 days of treatment have also presented worse quality and more methodological problems according to Downs and Black^[@B10]^. Furthermore, the clinical heterogeneity found was high. The heterogeneity in the meta-analysis describes the difference among the treatment effects, which means that these differences are not random. The differences among the studies are related to the sample size, time of follow up, and different study protocol^[@B37]^. Because of this heterogeneity, although our results pointed out that 60 days of treatment does not seem beneficial for patients with Chagas disease in the chronic phase, more studies are necessary.

Previous studies pointed out that a long treatment presents more adverse effects^[@B38]^. According to Aldasoro *et al*.^[@B38]^, there is a high frequency of adverse effects for the dose of 5 mg/kg/day when used for 60 days, with a significant disease burden for patients. In a retrospective study in which 23.2% of treatment interruption was observed, a multivariate analysis showed that this interruption was significantly associated with the severity of adverse effects^[@B39]^.

In the study of Álvarez *et al*.^[@B6]^, no serious adverse effects were reported and in only one case the treatment was discontinued. However, the standard dose was administered through a new intermittent dosing regimen. This has emerged as a potential therapeutic scheme for the treatment of patients with Chagas disease in the chronic phase, but it has not yet be confirmed by further long-term evaluations^[@B6],[@B8]^. Fabbro *et al*.^[@B23]^ have also administere the 5 mg/kg/day dose for 30 days, but only half the dose during the first week. However, no advantages were observed with the dose reduction only at the beginning of the treatment.

Two studies further evaluated the standard dose of benznidazole combined with another drug. Combination therapy has also been gaining attention as a possible strategy, since the association of molecules with different mechanisms of action could improve the pharmacokinetic profile, reducing the required drug dose, and increasing the treatment efficacy^[@B40]^. However, in STOP-CHAGAS, the combination of benznidazole and posaconazole showed no additional benefits compared with benznidazole in monotherapy, as both had similar negative PCR rates^[@B27]^. In the study by Perez-Mazliah *et al*.^[@B17]^, in which a sequential combination of benznidazole and allopurinol was used, significant changes in T and B cell responses, indicating a reduction in the parasite load, were observed. Studies with this type of therapy in humans, however, are still scarce, and further investigation is needed to define a better treatment combination.

Fernándes *et al*.^[@B11]^ tested a lower dose, between 2.5-55 mg/kg/day for 60 days. Negative PCR results were found in 100.0% of the participants and no serious adverse effects were reported. Molina *et al*.^[@B25]^ and Morillo *et al*.^[@B26]^, used 150 mg regimens for 60 days and 300 mg for 40 to 80 days respectively. However, even if they used half of the dose, there were serious adverse effects for both studies, which led to discontinuation of treatment. In addition, negative PCR results were in the 60.0% range. These findings reinforce the idea that higher doses as well as long-term treatment are not beneficial to patients.

Regarding the observed outcomes, it is known that in chronically infected patients, traditional parasitological methods are not as sensitive as in the acute phase and that *T. cruzi*-specific antibody titers take years to decrease^[@B8],[@B36]^. Thus, PCR is the most widely used and is considered a promising technique to detect therapeutic failure or success^[@B8]^. However, PCR was not used in all the studies, but many of them have combined two or more outcomes, allowing better evaluations.

Most authors pointed out as a limitation, the loss of participants during the treatment period. This loss is usually due to the high frequency of adverse effects reported by benznidazole users, which leads to treatment abandonment^[@B7]^. The short follow-up time was also cited as a limitation. As previously stated, long-term investigations are necessary to detect reliable negative results^[@B8],[@B36]^. Finally, the small sample number was also reported as a limitation. This is because with a small sample it is more difficult to obtain statistical power to answer the proposed hypotheses^[@B29]^.

In view of the above, it could be seen that the optimal dose regimen of benznidazole in the chronic phase of Chagas disease is still a matter of discussion today. Considering the results obtained in the present study and while an ideal dose is not defined, the standard dose of 5 mg/kg/day for 30 days seems to be the best option for the treatment of patients with Chagas disease in the chronic phase. However, investigations should be stimulated in order to reach a consensus on the best dose schedule for the chronic phase of the disease.
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